EV
Elikon Venture
Shanghai, ChinaFounded 2021
Elikon Venture is a venture capital firm based in Shanghai, China, focused on early-stage investments in biomedical innovation and healthcare. Founded in 2021, the firm partners with startups in the biotech and life sciences sector.
44% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $46.6M (across 15 rounds with reported amounts).
Portfolio
11
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
RZ
Ruochen Zhang
Associate Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| FFortitude Biomedicines, Inc. | Seed | $13M | Jan 2026 |
 Angitia Biopharmaceuticals | Series C | $120M | Dec 2024 |
 Innovac Therapeutics | Series A | $18M | Sep 2023 |
 Allorion Therapeutics | Series B | $50M | Mar 2023 |
| AAllorion | Series B | $50M | Mar 2023 |
| Angitia Biopharmaceuticals | Series B | $40M | Jan 2023 |
| AAngitia Bio | Series B | $40M | Jan 2023 |
| EEccogene | Series B | — | Jan 2023 |
 Ucello Therapeutics | Series A | $25M | Feb 2022 |
| AAngitia | Series B | $86M | — |
| AAngitia | Series D | $130M | — |
 CORE Biomedicine | Series A | $21M | — |
| FFortitude Biomedicines, Inc. | Seed | $13M | — |
 Fortitude | Seed | $13M | — |
| Allorion Therapeutics | Series A | $40M | — |
| AAllorion | Series A | $40M | — |
Top Co-Investors
OrbiMed5 shared
Legend Capital5 shared
IDG Capital4 shared
Morningside4 shared
Bain Capital Life Sciences2 shared
Acton Capital2 shared
Frazier Healthcare Partners2 shared
RA Capital Management2 shared
Med-Fine Capital2 shared
Oriza2 shared
WuXi AppTec1 shared
Vision Plus Capital1 shared
TFX Capital1 shared
Qiming Venture Partners USA1 shared
Lince Capital1 shared
Oriza Ventures1 shared
Wellington Management1 shared
Logos Capital1 shared
Hillhouse Investment1 shared
Last updated: 7 October 2026